Investing Center Preview – Manage your investments and watch your net worth grow.
PFE:NYSE – Large Cap Stock (Drug Manufacturers)
Pfizer Inc – PFE Stock Overview
Last Price | Today's Change | 52-Week Range | Trading Volume |
---|---|---|---|
21.84 | 0.00 (0.00%) | 21.44 - 31.54 | 641.1 thousand (Below Avg) |
Market data as of 4:00PM 04/08/25. Quotes are delayed by at least 15 min.
Overview - PFE
Open | -- |
---|---|
Previous Close | 21.84 |
Day's Range | -- - -- |
Market Cap | 123.9B |
Avg Volume (10 Day) | 57.5M |
Price/Earnings (Trailing 12 Mo.) | 16.0x |
Earnings Per Share (Trailing 12 Mo.) | 1.11 |
Dividend Yield | 0.43 (7.88%) |
One-Click Scorecard - PFE


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
Performed well consistently? | Fail |
---|---|
Avoids excess debt? | Pass |
Converting sales to profits? | Fail |
Shareholder's money handled rationally? | Pass |
Increased shareholder value? | Fail |
Consistently increased owner earnings? | Pass |
Sells at 25% discount to intrinsic value? | Pass |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
Pays a cash dividend? | Pass |
---|---|
Room to increase dividends? | Pass |
Increased earnings over time? | Pass |
Borrows within reasonable limits? | Pass |
Stock is undervalued? | Pass |
Have investors caught on? | Fail |
Has support of institutional investors? | Pass |
Has sufficient liquidity? | Pass |
Latest Headlines - PFE
European Commission Approves Pfizer’s RSV Vaccine ABRYSVO® to Help Protect Adults Aged 18-59 Against RSV Lower Respiratory Tract Disease
Business Wire - Tuesday 04/01/2025 3:00 AM ET
Dexcom Appoints Jon Coleman as Chief Commercial Officer
Business Wire - Tuesday 03/25/2025 4:05 PM ET
Pfizer Invites Public to View and Listen to Webcast of April 29 Conference Call with Analysts
Business Wire - Tuesday 03/18/2025 10:00 AM ET
ViiV Healthcare announces new implementation study data showing zero cases of HIV with Apretude, the only long-acting injectable approved for HIV PrEP
Business Wire - Wednesday 03/12/2025 3:08 PM ET
ViiV Healthcare’s investigational broadly neutralising antibody - N6LS - successfully maintains viral suppression in long-acting treatment of HIV
Business Wire - Wednesday 03/12/2025 11:30 AM ET
ViiV Healthcare showcases leadership in long-acting injectables innovation at CROI 2025 with data on third-generation integrase inhibitor (INSTI) and highly potent capsid inhibitor against HIV-1
Business Wire - Tuesday 03/11/2025 4:01 PM ET
Industry Position - PFE
PFE | Industry Range | |
---|---|---|
Revenue Growth (1yr) | 6.84% | |
Net Income Growth (1yr) | 279.00% | |
Total Debt/Equity | 0.72 | |
LT Debt/Equity | 0.64 | |
Earnings Yield | 6.23% | |
Price/Sales | 2.03 |
Competitors - PFE
Company | Last | Change |
---|---|---|
Gilead Sciences Inc | 103.19 | 0.00% |
6136.15 | +2.73% | |
205.87 | +0.52% | |
93.18 | +1.94% | |
Bristol-Myers Squibb Co | 53.07 | 0.00% |
Data is delayed by at least 15 min.